Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

NCT04565509 · View on ClinicalTrials.gov ↗

Study Summary

The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally the perceptions of COVID-19 and identify facilitators and barriers to help with the adoption of testing in other parts of the US and the necessary strategies to address other mitigation strategies including vaccination.

Interventions

  • DIAGNOSTIC_TEST COVID-19 Testing
  • BEHAVIORAL Focus Groups
  • BEHAVIORAL Standard Messaging
  • BEHAVIORAL Enhanced Messaging
  • BEHAVIORAL Fuzzy Cognitive Mapping

Study Locations (3)

Missouri

  • University of Missouri — Kansas City
  • Special School District — St Louis

Maryland

  • Hugo W. Moser Research Institute at Kennedy Krieger, Inc. — Baltimore

Trial Details

FieldValue
Enrollment Target 1,143 participants
Start Date 2020-11-20
Est. Completion 2024-03-29
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04565509

The ClinicalTrials.gov registry entry for NCT04565509 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,036 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Covid19 appearing as the primary indexed condition, and to 5 interventions — of which COVID-19 Testing is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04565509 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Missouri, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04565509 about?

NCT04565509 is a clinical study titled "Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic". The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally...

What is the current status of trial NCT04565509?

This trial is currently completed. It is a NA study. The enrollment target is 1,143 participants. The study started on 2020-11-20. Estimated completion is 2024-03-29.

What conditions does trial NCT04565509 study?

This clinical trial studies the following conditions: Covid19, Intellectual Disability, Developmental Disability, Child Development Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04565509?

The interventions under investigation include: COVID-19 Testing (DIAGNOSTIC_TEST), Focus Groups (BEHAVIORAL), Standard Messaging (BEHAVIORAL), Enhanced Messaging (BEHAVIORAL), Fuzzy Cognitive Mapping (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04565509?

This trial is sponsored by Washington University School of Medicine, which has 1,036 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04565509 being conducted?

This trial has 3 study locations across Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial